News >

Tumor-Treating Fields Extend Survival in Glioblastoma

Jason Harris
Published: Friday, Jan 19, 2018

brain cancer
Adding tumor-treating fields (TTFields) to temozolomide (Temodar) resulted in improved progression-free survival (PFS) and overall survival (OS) for patients with glioblastoma (GBM), according to a final analysis of results from the EF-14 trial.

= .58). Overall incidence, distribution, and severity of AEs were not statistically different in patients in the 2 treatment groups. Investigators observed a higher number of some AEs in the TTFields plus temozolomide group, but concluded that was “a reflection of the longer duration of temozolomide treatment in this group due to delayed occurrence of progression.”
Stupp R, Tailibert S, Kanner A, et al. Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: A randomized clinical trial. JAMA. 2017;318:2306-2316. doi: 10.1001/jama.2017.18718.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication